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Abstract
Objectives: Detection of carriage rate of Streptococcus pneumoniae 
from children in Wadi Al Seer district, Jordan.
Methods: Nasopharyngeal were collected from 118 children aged be-
tween one to 50 months. S. pneumoniae isolates were analysed for 
resistance, serotyping and macrolide resistant genotypes and pheno-
types.
Results: Carriage rate was 55.1% (n= 65/118). Resistance rate was 
as follows: Penicillin (80%), trimethoprim-sulfamethoxazole (73.8%), 
erythromycin (61.5%), tetracycline (53.8%) and clindamycin (33.8%), 
Multidrug resistant isolates were 56.9%. (MIC50 & MIC90 µg/ml) were 
as follows: Penicillin (0.5,2), erythromycin (2, >=32), clindamycin (0.06, 
>=32), trimethoprim-sulfamethoxazole (4, >=32). M-Phenotypes 
(45%), iMLSB (2.5%) and cMLSB (52.5%) with genotypes erm(B) 55%, 
and mef(A) 45%. Common serotypes were: 19F (18.5%), 6B (16.9%), 
23F (12.3%), 35B (6.2%). Coverage of PCV7, PCV10 and PCV13 was 
52.3%, 52.3% and 58.5%, respectively. 
Conclusions: High rates of S. pneumoniae carriage and drug resistance 
is a potential serious risk to increase pneumococcal invasive and non 
invasive infections in Jordanian children. 
Keywords: Streptococcus pneumoniae, Resistance, Colonization, Jor-
dan.
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Introduction
Streptococcus pneumoniae is a leading cause of 
bacterial pneumonia, meningitis, bacteraemia, oti-
tis media, and sinusitis and continues to be a signif-
icant cause of morbidity and mortality in humans 
[1]. The worldwide increase in antibiotic resistance 
in these species has become a serious problem 
within the last twenty years [2]. S. pneumoniae 
was given the name as the forgotten killer in chil-
dren in 2008 by the WHO [3], which accounts for 
more than one third of acute bacterial sinusitis and 
more than one half of community-acquired bacte-
rial pneumonia [4]. It remains a major cause of 
childhood morbidity and mortality, where at least 
1.2 million children die of pneumococcal infections 
each year as stated by the WHO in 2007 and 70% 
of them in Africa and southeast Asia; mostly in 
developing countries [5]. 
Antibiotic treatment of invasive disease has been 
widely countered by the increasing emergence of 
resistance in many parts of the world in the recent 
years. Resistance to beta-lactam, macrolides, tet-
racycline and trimethoprim-sulfamethoxazole were 
reported [6]. However, the resistance pattern varied 
greatly from country to country [7]. This emphasises 
the importance of local data in determining the ap-
propriate antibiotic therapy.
S. pneumoniae is a common colonizing bacterium 
in the respiratory tract, mostly symptom less; how-
ever it can progress to respiratory or even systemic 
disease. An important feature is that pneumococcal 
disease will not occur without preceding nasopha-
ryngeal colonization with the homologous strain, so 
pneumococcal carriage is believed to be an impor-
tant source of horizontal spread of this pathogen 
within the community [8]. Increased prevalence of 
S. pneumoniae in healthy children’s nasopharynx 
reflects a potential risk to develop more frequently 
respiratory infections in the community [9,10]. 
There is only one old Jordanian study published in 
2000 which has reported on the antimicrobial sus-
ceptibility pattern of S. pneumoniae isolates from 
various clinical specimens, and this study showed 
that 56% of the isolates were penicillin resistant 
[11], however, recent data about prevalence of an-
timicrobial susceptibility pattern of this organism in 
children population are not available. Furthermore, it 
is essential to determine the distribution of S. pneu-
moniae serotypes among children in each country in 
order to address the actual value of using available 




One hundred and eighteen children aged 1 month to 
50 months were chosen randomly from the Maternity 
Health Center of Wadi Al Seer district in Amman to be 
included in this during 2009. The study has involved 
7 smaller neighborhoods. The recruitment phase 
started by sending letters explaining the purpose of 
the study and containing consent form and question-
naire regarding potential risk factors for the carriage 
of S. pneumoniae were sent to parents. Only children 
whose parents consented to participate were enrolled 
in the study. Also, at the time of the study, all investi-
gated children were admitted to the Maternity Health 
Care Center for the periodic checkups, and these were 
not vaccinated with the 7 valent pneumococcal conju-
gate vaccine (PCV7, Pfizer Inc., USA).
Specimen collection and transport
Sterile nasopharyngeal and throat swabs pre-moist-
ened with sterile water were taken by the medical 
doctor from each child [13]. The swabs were trans-
ported in ice box to the laboratory within 4 hours 
for culture. 
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Bacterial identification
In the laboratory, each swab specimen was mixed 
thoroughly using a vortex mixer before inocula-
tion onto Colombia blood agar base (Oxoid, UK) 
supplemented with 5% sheep blood (Oxoid, UK). 
Plates were incubated at 37°C for 24h-48h with 5% 
CO2. S. pneumoniae colonies were selected based 
on colony morphology, a-haemolysis, susceptibility 
to optochin, and bile solubility, then pneumococ-
cal colonies were purified and stored at -20°C for 
further work [14].
Susceptibility testing
Minimal inhibitory concentration (MIC) testing was 
performed using the broth microdilution method as 
recommended by the Clinical Laboratory Standards 
Institute (CLSI) [15]. S. pneumoniae ATCC 49619 
was used as a control strain. 
Serotyping
Serotypes were done by the Neufeld Quellung reac-
tion method with the available antisera from Statens 
Serum Institute of Copenhagen-Denmark [16]. This 
part of work was performed at the National Refer-
ence Center for Streptococci in Germany.  
Analysis of resistance determinants
PCR of macrolide resistance determinants was per-
formed as described previously [17]. For the classical 
detection of erm(B) and mef(A) the following prim-
ers were used: erm(B) 5´-CGAGTGAAAAAGTACT-
CAACC-3´ (362-382) and 5´-GGCGTGTTTCATT-
GCTTGATG-3´ (978-958), mef(A) 5´-AGTATCAT-
TAATCACTAGTGC-3´ (57-77) and 5´-TAATAGATG-
CAATCACAGC-3` (550-532). The macrolide resis-
tance phenotype was determined on the basis of 
the pattern of susceptibility to MLSB (macrolide-
lincosamide-streptogramin B) [18]. 
Results
S. pneumoniae carriage rate
A total of 65/118 children (55.1%) were found to 
carry S. pneumoniae in the nasopharynx (Table 1). 
Table 1.  Distribution of carriage rates in different age groups of the children in association  
with the coverage of pneumococcal conjugate vaccines* 
Age (Years) 
No. of carriers**/ Total 
No. of children (%)
coverage 7v PCV 
(%)
coverage 10v PCV 
(%)
coverage 13v PCV 
(%)
<= 1 year 42/ 65 (64.6%) 20/42 (47.6) 20/42 (47.6) 22/42 (52.4)
>1- 2 16/ 31 (51.6%) 10/ 16 (62.5) 10/ 16 (62.5) 11/ 16 (68.8)
>2- 3 4/ 13 (30.8%) 2/4 (50) 2/4 (50) 3/4 (75)
>3 years- 50 months 3/9 (33.3%) 2/3 (66.6) 2/3 (66.6) 2/3 (66.6)
Birth - 2 years 58/ 96 (60.4%) 30/58 (51.7) 30/58 (51.7) 33/58 (56.9)
(Total ) 0- 50 months 65/118 (55.1%) 34/65 (52.3) 34/65 (52.3) 38/65 (58.5)
* A total of 51.2% the examined children showed upper respiratory tract infection, and 27.1% were previously treated with antibiotics
** S. pneumoniae was isolated at the same time from 12% of both throat and nasopharynx swab specimens. 
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The mean age of children was 13.4 months, and 
the range of age was 1 to 50 months. The children 
included 51.7% males and 48.3% females. A total 
of 31/118 (27.1%) have been treated previously with 
antibiotics. 
Antimicrobial susceptibility
The percentage of resistance among S. pneumoniae 
was as follows: Penicillin G (80%), trimethoprim-
sulfamethoxazole (73.8%), tetracycline (53.8%), 
erythromycin (61.5%) and clindamycin (33.8%). 
Vancomycin, amoxicillin, cefotaxime, levofloxacin 
and telithromycin showed no resistance. Minimal 
inhibitory concentrations of S. pneumoniae isolates 
(MIC50, MIC90 µg/ml) were as follows: Penicillin 
(0.5, 2), erythromycin (2, >=32), clindamycin (0.06, 
>=32), trimethoprim-sulfamethoxazole (4, >=32), tet-
racycline (16, 32), and levofloxacin (0.5, 1) (Table 2). A 
total of 37 isolates (56.9%) were Multidrug resistant 
and were belonged mostly to serotypes available in 
the pneumococcal conjugate vaccines (6B, 6A, 14, 
19A, 19F and 23F) (Table 4). 
Macrolide resistant pheno- and genotypes
Resistance to erythromycin A accounted to 61.5% 
(n= 40) of S. pneumoniae isolates. Of these two 
different phenotypes of macrolide resistance were 
found. MLSB constitutive phenotype accounted to 
52.5% of isolates (n= 21), and 45% (18 isolates) had 
the M-phenotype, and 2.5% (1 isolate) was induc-
ible MLSB (Table 3). It was observed that penicillin 
resistant strains had higher MICs towards macrolide 
drug. Macrolide resistant genotypes were divided in 
ermB (55%; 22 isolates) and mefA (45%; 18 isolates) 
(Table 3).  
Serotyping
The most common serotypes indicated were the 
following: 19F (18.5%), 6B (16.9%), 23F (12.3%), 
Table 2. Ranges of MIC50, MIC90,and antibiotic resistance patterns of 65 isolates of S. pneumoniae
Antibiotic MIC range (n=65) (n) % resistance (I, R) % Sensitive MIC50 MIC90
Penicillin G 0.016- 8 (52) 80 20 0,5 2
Erythromycin A 0.06- >=32 (40) 61.5 38.5 2 >=32
Clindamycin 0.06- >=32 (22) 33.8 66.8 0,06 >=32
Sulfameth. Trimeth. 0.06- >=32 (48) 73.8 26.2 4 >=32
Tetracycline 0.25-32 (35) 53.8 46.2 16 32
Vancomycin <=2 (0) 0 100 <=2 <=2
Levofloxacin 0.5-2 (0) 0 100 0,5 1
Amoxicillin 0.016- 1 (0) 0 100  0.03  0.06
Cefotaxime 0.016- 0.5 (0) 0 100  0.016  0.03
Telithromycin 0.016- 0.5 (0) 0 100  0.016  0.03
a  Breakpoints (I, R) according to CLSI: Penicillin G: (0.1–1 µg/ml, ³2 µg/ml); cefotaxime: (2 µg/ml, ³ 4 µg/ml); erythromycin A 
(0.5 µg/ml, ≥ 1 µg/ml); clindamycin :(0.5 µg/ml, ³ 1 µg/ml); tetracycline: (4 µg/ml ³ 8 µg/ml); trimethoprim-sulfamethoxazole: 
(1/19-2/38 µg/ml, ³ 4/76 µg/ml); and all isolates were susceptible for vancomycinat MIC ≤ 1 µg/ml.
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35B (6.2%), 11A, NT and 15A (4.6%) each isolated, 
followed by serotypes 14, 34, 23A, 6A, and 19A 
with 3.1% each isolated (Table 3).
Coverage of the pneumococcal  
conjugate vaccines
The total coverage of the PCV7 among all children 
with positive isolates was (55.1%). Coverage of 
PCV7, PCV10 and PCV13 was 52.3%, 52.3% and 
58.5%, respectively. Although the highest coverage 
of the 7v-PCV (66.6%) was observed among infants 
aged between 2 to 3 years of age but the total 
number of these children was 13 in the study. In 
children below one year of age (n=65), coverage of 
the PCV7 was 64.6% (Table 1). 
Table 3. Distribution of S. pneumoniae serotypes and macrolide resistant pheno-genotypes among ex-





19F 6B 23F 35B 11A 15A NT 14 34 6A 23A 19A *Others M-Ph cMLSB iMLSB ermB mefA
Number 12 11 8 4 3 3 3 2 2 2 2 2 11 18 21 1 22 18
Percentage 18.5 16.9 12.3 6.1 4.6 4.6 4.6 3.1 3.1 3.1 3.1 3.1 16.9 45 52.5 2.5 55 45
* Other serotypes; 33F, 15B, 15F, 16F, 17F, 18A, 22F, 33A, 35A, 7B, and 9V each of these serotypes was detected one time with (1.5%) 
Table 4. Resistance patterns according to the serotype of S. pneumoniae isolates
Serotype
No. ( % ) 
of isolates
 















6B 11 (16.9) 10 (90.9) 7 (63.6) 8 (72.7) 8 (72.7) 10 (90.9) 7 (63.6) 7 (63.6)
9V 1 (1.5) 1 (100) 1 (100) 1 (100) 0 (0) 1 (100) 1 (100) 1 (100)
14 2 (3.1) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100) 2 (100)
19F 12 (18.5) 11 (91.7) 11 (91.7) 10 (15.4) 5 (7.7) 12 (100) 9 (75) 5 (7.7)
23F 8 (12.3) 8 (100) 7 (87.5) 4 (50) 0 (0) 8 (100) 4 (50) 4 (50)
19A 2 (3.1) 2 (100) 1 (50%) 2 (100) 1 (50%) 1 (50%) 0 (0) 2 (100)
6A 2 (3.1) 2 (100) 1(50%) 2 (100) 2 (100) 1(50%) 2 (100) 2 (100)
aOthers 27 (41.5) 16 (59.3) 9 (33.3) 11 (40.7) 4 (14.8) 13 (48.1) 9 (33.3) 14 (14.8)
Total 65 52 (80) 39 (60) 40 (61.5) 22 (33.8) 48 (73.8) 34 (52.3) 37 (56.9)
aOthers: Serotypes not included in the 7 valent pneumococcal conjugate vaccine. Serotypes 4 and 18C were not found in this study. 
Abbreviations: PEN, Penicillin; FUR, Cefuroxime; ERY, Erythromycin; CLI, Clindamycin; SXT, Sulfamethoxazole-Trimethoprim; TET, Tetracyclin
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DISCUSSION
To our knowledge, this is the first data from Jor-
dan which describe the pneumococcal serotypes 
colonized in the pediatric population of one dis-
trict in Jordan. Nasopharynx is the usual source of 
pneumococci for studying the carriage rate [19]. 
This study has demonstrated that carriage rate of 
S. pneumoniae among children in Jordan is high 
(55.1%) compared to the study reported by Lee et 
al., for carriage rate of pneumococci in 4963 Asian 
children aged below 5 years from 11 countries [ 20 
]. The results of the study investigated showed the 
following rates: Philippines (32.6%), China (37.5%), 
India (43.2%) and Thailand (40.6%), but lower rates 
in Taiwan (15.3%) and Saudi Arabia (9.0%). Similar 
carriage rates were obtained from Brazil (55%) [12], 
Guatemala (59.1%) [21], and in Kampala Uganda 
(62%) [22]. The high rate of pneumococci coloni-
zation can be due to different factors such as his-
tory of sicknesses, immune deficiency, viral infec-
tions and history of antibiotic consumption before 
attending the Daily Care Center (DCC) as the case 
with our investigated children. Since 51.2% of our 
examined children had suffered of upper respira-
tory tract infections before admission to the DCC, 
and data taken from children’s medical records of 
the DCC showed that 27.1% had a history of anti-
biotic consumption prior to their visits to the DCC, 
which could be contributed for selection of resis-
tant strains [18]. The differences in carriage rates 
worldwide were related to certain socio-economic 
conditions including housing, access to health care, 
poor hygiene, family size, overcrowded living con-
ditions, day-care contact, and number of siblings 
[23]. Previous studies reported the attendance of 
day care as a main factor causing the increase of 
the carriage rate of S. pneumoniae [24]. Continuous 
surveillance of the susceptibility patterns of S. pneu-
moniae becomes increasingly important, because 
of the increasing emergence of antibiotic-resistant 
strains worldwide [25]. 
This study suggests that prior antibiotic use is not 
only an important risk factor for an increased S. 
pneumoniae carriage but may be also considered a 
risk factor for carriage of multiple-resistant strains 
of pneumococci. The antibiotics susceptibility of the 
S. pneumoniae isolated from our children’s naso-
pharynx reflected alarming rates of resistance to 
penicillin, erythromycin and occurrence of multi-
drug-resistant isolates. Rates of antibiotic resistant 
of S. pneumoniae isolates among our children were 
higher than those clinical isolates from Singapore 
and Sri Lanka but similar to Taiwan [20]. However, 
our resistance rates resemble the rates reported in 
some other Asian countries [26]. The high rates of 
resistance to different classes of antibiotics in S. 
pneumoniae in this study are presumably a conse-
quence of antimicrobial consumption and its mis-
use within the Jordanian population [27]. Otoom 
et al., (2002) reported that antibiotic prescriptions 
in Jordan at different health centers ranged be-
tween 46.7% to 83.3%; and these rates are very 
high compared to many other parts of the world 
[28]. Local information on capsular types of S. pneu-
moniae causing disease in young children is highly 
important to guide production of effective conju-
gate vaccine. Our results of S. pneumoniae serotyp-
ing showed that most prevalent serotype was 19F 
(18.5%) followed by 6B (16.9%) then 23F (12.3%). 
Similar serotyping results has been reported from-
Kuwait among S. pneumoniae isolates from children 
(6B and 23F had a prevalence of 9%, and 19F ac-
counted for 9.8%)  [29]. A study by Marchisio et al. 
(2002)in Italy, has found that S. pneumoniae carrier 
rate was 8.6% and included the following serotypes 
(3, 19F, 23F, 19A, 6B, and 14), and that most of 
pneumococci isolates (69.4%) were resistant to one 
or more antimicrobial classes [21]. Whereas children 
aged 3-36 months attending day care centers in Bel-
gium, had 21 % S. pneumoniae carriage rate and 
the main serotypes were 19F (27.3%), 6B (20.2%), 
23F (19.2%), 19A (10.1%), 6A (7.1%), 14 (5.1%) [19]. 
Prevenar, the 7-valent pneumococcal conjugate vac-
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cine (PCV7) and the new 13-valent pneumococcal 
conjugate vaccine (PCV13) are used routinely in the 
National Immunization Program of several industri-
alized nations. This study shows that both vaccines 
are covering 52.3% and 58.5% of S. pneumoniae 
serotypes distributed among our children, respec-
tively. Around the world, the highest coverage for 
PCV7 has been reported for the USA, Canada, and 
Australia (80–90%), followed by Europe and Africa 
(70–75%), whereas in Latin America and Asia the 
coverage rates were 65% and 50%, respectively 
[30]. Finally, our study was only performed in a small 
group of children and one district of the capital Am-
man. We are aware that the carriage patterns may 
vary between various communities and it is possible 
that the serotype distribution and resistance pat-
terns described here may not be representative to 
the overall population of children in Jordan. 
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